Key Financial Results for Half Year Ended 31st March 2025

Income Statement (Amounts in ₹ lakhs):

  • Revenue from Operations: ₹5,024.80
  • Other Income: ₹10.34
  • Total Income: ₹5,035.14
  • Cost of Material Consumed: ₹2,855.77
  • Purchase of Traded Goods: ₹751.72
  • Employee Benefits Expense: ₹331.85
  • Finance Costs: ₹191.08
  • Depreciation and Amortization: ₹245.64
  • Other Expenses: ₹413.82
  • Total Expenses: ₹4,607.51
  • Profit Before Tax: ₹427.63
  • Current Tax: ₹123.71
  • Deferred Tax: (₹17.71)
  • Net Profit: ₹321.63

Earnings Per Share:

  • Basic EPS: ₹4.17 (not annualized)
  • Diluted EPS: ₹4.17 (not annualized)

Capital Structure:

  • Paid-up Equity Share Capital: ₹772.10 lakh (face value ₹10 each)
  • Other Equity: ₹1,069.13 lakh

Full Year Financial Results for FY25 (Amounts in ₹ lakhs):

  • Revenue from Operations: ₹9,751.83
  • Other Income: ₹18.93
  • Total Income: ₹9,770.77
  • Net Profit: ₹535.05
  • Basic EPS: ₹6.94
  • Diluted EPS: ₹6.94

Significant Corporate Events

1. Equity Share Allotment: On 22nd April 2024, the company allotted 1,21,000 fresh equity shares at an issue price of ₹100 per share (₹10 face value + ₹90 securities premium).

2. BSE SME Listing: The company successfully debuted on the BSE SME platform on June 3, 2025. As part of its public offering, the company issued 27,90,000 equity shares at ₹135 per share (₹10 face value + ₹125 securities premium). The allotment was completed on May 30, 2025.

3. Registered Office Change: The Board approved the change of Registered Office from #1358, First Floor, Sector 22 B, Chandigarh to SCO 186-187, 2nd Floor, Cabin No. 206, Sector 8-C, Chandigarh - 160009, effective from 19th December 2024.

Operational and Accounting Notes

  • The company operates in a single segment - manufacture and sale of drugs & cosmetics
  • No separate reportable segments except geographically secondary segment of export sales
  • No exceptional or extraordinary items reported for the period
  • Previous year figures have been reclassified for better comparability regarding traded purchases
  • The second half FY25 figures are balancing figures between audited full year and unaudited YTD September 2024 figures

Management and Governance

  • Company Secretary Avneet Kaur resigned effective 4th July 2025
  • Managing Director Ashish Gulati is overseeing secretarial and compliance affairs until replacement
  • Financial results certified by Managing Director and CFO as required under Regulation 33